Anticoagulant News and Research

RSS

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

Tifacogin administration shows no treatment benefit in patients with severe CAP

Use of the blood clot-inhibiting medication tifacogin does not appear to improve outcomes of patients with severe community-acquired pneumonia, according to a study conducted by researchers from North and South America, Europe, Asia and Africa. The drug had shown some potential benefit in the sCAP subgroup of an earlier trial involving sepsis patients.

23 Feb 2011

Study: Ventilator-associated pneumonia infections drop by 70% in Michigan hospitals

Cases of ventilator-associated pneumonia — the most lethal and among the most common of all hospital-associated infections — dropped by more than 70 percent in Michigan hospitals where medical staff used a simple checklist designed by Johns Hopkins researchers. Such pneumonias kill an estimated 36,000 Americans each year.

17 Feb 2011

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

ThromboGenics NV and co-development partner BioInvent International announce today that the positive TB-402 Phase II trial results, evaluating the product's efficacy and safety for the prevention of venous thromboembolism afterorthopaedic surgery, have been published in the Journal of Thrombosis and Haemostasis.

14 Feb 2011

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

Genetic testing for inherited blood-clotting abnormalities is not routinely recommended for patients with venous thromboembolism (VTE) of unknown cause, according to a new expert panel statement in a recent issue of Genetics in Medicine, the official peer-reviewed journal of The American College of Medical Genetics (ACMG).

11 Feb 2011

New findings of drug recently identified to prevent stroke in patients with AF published in NEJM

New findings from a McMaster University-led study of a drug recently identified to prevent stroke in patients with atrial fibrillation have been published in the high-impact New England Journal of Medicine today.

11 Feb 2011

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has initiated a Phase 2 clinical trial, following conclusion of a review by the United States Food and Drug Administration (FDA) of a protocol submitted by PolyMedix, to assess the safety and efficacy of its heptagonist, PMX-60056, in reversing heparin in patients undergoing Percutaneous Coronary Intervention (PCI) procedures.

9 Feb 2011

DE-MRI holds promise for predicting risks of strokes

Researchers at the University of Utah's Comprehensive Arrhythmia and Research Management Center have found that delayed-enhancement magnetic resonance imaging holds promise for predicting the risks of strokes, the third leading cause of death in the U.S.

9 Feb 2011

Pharmacist-directed anticoagulation service improves quality of care for HIT patients

A Henry Ford Hospital study has found that a pharmacist-directed anticoagulation service improves the way medication is managed for patients with heparin-induced thrombocytopenia, a common but life-threatening thromboembolic disorder.

9 Feb 2011

Scientists discover how stressed cells boost thrombin production

In our not-so-distant evolutionary past, stress often meant imminent danger, and the risk of blood loss, so part of our body's stress response is to stock-pile blood-clotting factors. Scientists in the Molecular Medicine Partnership Unit, a collaboration between the European Molecular Biology Laboratory in Heidelberg, Germany, and the University of Heidelberg Medical Centre, have discovered how stressed cells boost the production of the key blood-clotting factor, thrombin.

4 Feb 2011

Scientists discover how stressed cells boost production of key blood-clotting factor, thrombin

Scientists in a collaboration between EMBL Heidelberg and the University of Heidelberg Medical Centre have discovered how stressed cells boost the production of the key blood-clotting factor, thrombin. Their work, published today in Molecular Cell, shows how cancer cells may be taking advantage of this process, and opens new possibilities for fighting back against cancer and septicaemia.

4 Feb 2011

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

An American dies of heart disease every 39 seconds, and African Americans suffer a higher death rate from heart disease and stroke than Americans overall. Partly as a result of having the highest prevalence of high blood pressure in the world, African Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

1 Feb 2011

Red wine polyphenols prevent ageing-induced endothelial dysfunction

The endothelium is the inner lining of our blood vessels and normal functions of endothelial cells include enabling coagulation, platelet adhesion and immune function. Endothelial dysfunction is associated with reduced anticoagulant properties and the inability of arteries and arterioles to dilate fully.

1 Feb 2011

Scientist identifies natural signaling molecule that can prevent Hemophilia A

A scientist from The Scripps Research Institute has identified a new role for a natural signaling molecule in preventing blood clot formation. The molecule could become a target for the development of novel and cost-effective treatments for blood clotting diseases such as Hemophilia A.

1 Feb 2011

Patients unaware of stroke risk with irregular heart beat conditions

Thousand of people who suffer from irregular heartbeats or conditions termed as arrhythmias are unaware they are at high risk of suffering a stroke. A new survey found that two of three people do not know the warning signs of shortness of breath and palpitations. Experts estimate that more than 4,000 strokes a year could be prevented by better awareness among the general public and doctors of the heart condition atrial fibrillation (AF) this manifests as palpitations and irregular heart beat.

31 Jan 2011

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Johnson & Johnson today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%.

25 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

Anticoagulant News and Research

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

Tifacogin administration shows no treatment benefit in patients with severe CAP

Study: Ventilator-associated pneumonia infections drop by 70% in Michigan hospitals

JTH publishes positive TB-402 Phase II trial results for VTE treatment after orthopaedic surgery

Genetic testing for inherited blood-clotting abnormalities not routinely recommended for VTE patients

New findings of drug recently identified to prevent stroke in patients with AF published in NEJM

PolyMedix commences PMX-60056 Phase 2 clinical trial in patients undergoing PCI

DE-MRI holds promise for predicting risks of strokes

Pharmacist-directed anticoagulation service improves quality of care for HIT patients

Scientists discover how stressed cells boost thrombin production

Scientists discover how stressed cells boost production of key blood-clotting factor, thrombin

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

Red wine polyphenols prevent ageing-induced endothelial dysfunction

Scientist identifies natural signaling molecule that can prevent Hemophilia A

Patients unaware of stroke risk with irregular heart beat conditions

Johnson & Johnson fourth quarter sales decreases 5.5% to $15.6 billion

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

Boston Scientific announces merger agreement to acquire Atritech

Dextran-coated onto iron oxide nanoparticles can detect cholera toxin: Study

Study reports warfarin users may face risk of death after traumatic injuries

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News